Atara Biotherapeutics (ATRA) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atara Biotherapeutics (ATRA) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 53.7% versus a loss of 76.7%. Over five years, TNYA leads with a -98.5% price change compared with -98.6% for ATRA. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $64.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | TNYA |
|---|---|---|
| Share price | $6.33 | $0.2866 |
| Market cap | $64.49M | $65.32M |
| 1-day change | -0.16% | -3.99% |
| YTD return | -65.01% | -59.75% |
| 1-year return | -53.73% | -76.70% |
| 5-year return | -98.56% | -98.50% |
| Forward P/E | 3.96 | — |
| EPS (TTM) | $-1.12 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $120.77M | — |
| Revenue growth (YoY) | -6.33% | — |
| Net income (latest FY) | $32.69M | $-90.60M |
| Operating margin | 29.69% | — |
| Net margin | 27.07% | — |
| 52-week high | $19.15 | $1.46 |
| 52-week low | $3.92 | $0.28 |
| Distance from 52-week high | -66.94% | -80.37% |
| Analyst consensus | buy | none |
| Avg. price target upside | +115.96% | +1016.54% |
| Average volume | 35.46K | 2.96M |
| Shares outstanding | 10.19M | 227.93M |
| Employees | 10 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRA has outperformed TNYA by 23.0 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
ATRA vs TNYA FAQ
Which is bigger, Atara Biotherapeutics or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $64.49M for Atara Biotherapeutics (ATRA).
Which stock has performed better over the past year, ATRA or TNYA?
ATRA returned -53.73% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.